- Published on
Infectious Disease and Microbiology – Anthrax
Anthrax is a zoonotic infection primarily affecting herbivorous animals and only occasionally humans. The term derives from the Greek word for coal, referring to the characteristic black eschar seen in cutaneous disease. In humans, anthrax presents in three principal forms: cutaneous, inhalational (respiratory), and gastrointestinal. The incubation period ranges from 3–10 days for cutaneous disease and 3–5 days for pulmonary disease. Although rare in the United States, anthrax has been associated with exposure to contaminated wool, hides, and animal products, as well as foodborne outbreaks from tainted meat. The 2001 bioterrorism-related outbreak in the US resulted in 22 cases, including 11 inhalational cases and 5 deaths. A newer “injectional” form has been described among injection drug users, notably in Scotland, with significant mortality.
The causative agent, Bacillus anthracis, is an aerobic, gram-positive, spore-forming bacillus. Its spores are highly resistant to environmental stressors such as drying, radiation, and disinfectants and can persist in soil for years. Major risk factors in endemic developing regions include contact with contaminated soil or infected animals, while in urban areas exposure to contaminated animal products is more common. Prevention strategies include livestock vaccination, decontamination of animal products, and vaccination of high-risk groups such as military personnel, veterinarians, and individuals handling imported hides.
The pathogenesis of anthrax depends largely on the production of two binary toxins: lethal toxin and edema toxin. These toxins disrupt host immune responses and contribute to tissue necrosis, edema, and systemic toxicity. Clinically, cutaneous anthrax is the most common presentation. It begins as a painless papule that progresses to a vesicle and then to a characteristic black eschar measuring 1–3 cm, surrounded by edema. If untreated, cutaneous infection may progress to bacteremia and sepsis.
Inhalational anthrax often presents in two phases. The initial phase resembles a nonspecific viral upper respiratory illness lasting several days, followed by rapid deterioration with severe pneumonitis, respiratory distress, and systemic toxicity. Mediastinal widening on chest radiograph is a hallmark finding in advanced disease. The combination of mediastinal widening, altered mental status, and elevated hematocrit has been reported as highly sensitive in distinguishing inhalational anthrax from community-acquired pneumonia. Gastrointestinal anthrax presents with abdominal pain, nausea, vomiting, fever, and may include hematemesis or hematochezia. Injectional anthrax, seen in injection drug users, manifests with severe soft tissue infection, marked edema, and may include intracranial hemorrhage or gastrointestinal symptoms. Meningoencephalitis can complicate any form through hematogenous spread and may present with hemorrhagic cerebrospinal fluid and rapid progression to coma.
Diagnosis relies on clinical suspicion and laboratory confirmation. Gram stain and culture of vesicular fluid from cutaneous lesions typically demonstrate large, encapsulated gram-positive rods in short chains. Blood cultures are often positive in systemic disease, and stool cultures may reveal the organism in gastrointestinal infection. Chest imaging may show infiltrates, pleural effusions, and mediastinal widening. Differential diagnosis varies by presentation and includes tularemia, staphylococcal infections, spider bites, burns, bacterial or viral pneumonias, enteric bacterial infections, tuberculosis, and viral or amebic meningoencephalitis.
Treatment depends on disease severity and route of acquisition. Uncomplicated cutaneous anthrax in individuals older than two years can be treated with oral ciprofloxacin or doxycycline for 7–10 days. If susceptibility is confirmed, penicillin or amoxicillin may be used. Severe cutaneous disease requires intravenous therapy. Inhalational, gastrointestinal, or systemic anthrax requires prompt intravenous combination therapy, typically including ciprofloxacin plus one or two additional agents such as a carbapenem, rifampin, vancomycin, penicillin, chloramphenicol, or clindamycin. At least one agent with good central nervous system penetration should be included due to the risk of meningitis. In bioterrorism-related exposure, prolonged therapy for 60 days is recommended. Raxibacumab, a monoclonal antibody targeting anthrax toxin, has shown benefit in animal models of inhalational disease.
Prognosis depends on the form of disease and timeliness of treatment. Cutaneous anthrax generally responds well to therapy but often leaves a residual scar. Inhalational and gastrointestinal forms carry high mortality rates if not treated promptly. Close follow-up is required to monitor for recurrence or complications.
Anthrax is a zoonotic infection primarily affecting herbivorous animals and only occasionally humans. The term derives from the Greek word for coal, referring to the characteristic black eschar seen in cutaneous disease. In humans, anthrax presents in three principal forms: cutaneous, inhalational (respiratory), and gastrointestinal. The incubation period ranges from 3–10 days for cutaneous disease and 3–5 days for pulmonary disease. Although rare in the United States, anthrax has been associated with exposure to contaminated wool, hides, and animal products, as well as foodborne outbreaks from tainted meat. The 2001 bioterrorism-related outbreak in the US resulted in 22 cases, including 11 inhalational cases and 5 deaths. A newer “injectional” form has been described among injection drug users, notably in Scotland, with significant mortality.
The causative agent, Bacillus anthracis, is an aerobic, gram-positive, spore-forming bacillus. Its spores are highly resistant to environmental stressors such as drying, radiation, and disinfectants and can persist in soil for years. Major risk factors in endemic developing regions include contact with contaminated soil or infected animals, while in urban areas exposure to contaminated animal products is more common. Prevention strategies include livestock vaccination, decontamination of animal products, and vaccination of high-risk groups such as military personnel, veterinarians, and individuals handling imported hides.
The pathogenesis of anthrax depends largely on the production of two binary toxins: lethal toxin and edema toxin. These toxins disrupt host immune responses and contribute to tissue necrosis, edema, and systemic toxicity. Clinically, cutaneous anthrax is the most common presentation. It begins as a painless papule that progresses to a vesicle and then to a characteristic black eschar measuring 1–3 cm, surrounded by edema. If untreated, cutaneous infection may progress to bacteremia and sepsis.
Inhalational anthrax often presents in two phases. The initial phase resembles a nonspecific viral upper respiratory illness lasting several days, followed by rapid deterioration with severe pneumonitis, respiratory distress, and systemic toxicity. Mediastinal widening on chest radiograph is a hallmark finding in advanced disease. The combination of mediastinal widening, altered mental status, and elevated hematocrit has been reported as highly sensitive in distinguishing inhalational anthrax from community-acquired pneumonia. Gastrointestinal anthrax presents with abdominal pain, nausea, vomiting, fever, and may include hematemesis or hematochezia. Injectional anthrax, seen in injection drug users, manifests with severe soft tissue infection, marked edema, and may include intracranial hemorrhage or gastrointestinal symptoms. Meningoencephalitis can complicate any form through hematogenous spread and may present with hemorrhagic cerebrospinal fluid and rapid progression to coma.
Diagnosis relies on clinical suspicion and laboratory confirmation. Gram stain and culture of vesicular fluid from cutaneous lesions typically demonstrate large, encapsulated gram-positive rods in short chains. Blood cultures are often positive in systemic disease, and stool cultures may reveal the organism in gastrointestinal infection. Chest imaging may show infiltrates, pleural effusions, and mediastinal widening. Differential diagnosis varies by presentation and includes tularemia, staphylococcal infections, spider bites, burns, bacterial or viral pneumonias, enteric bacterial infections, tuberculosis, and viral or amebic meningoencephalitis.
Treatment depends on disease severity and route of acquisition. Uncomplicated cutaneous anthrax in individuals older than two years can be treated with oral ciprofloxacin or doxycycline for 7–10 days. If susceptibility is confirmed, penicillin or amoxicillin may be used. Severe cutaneous disease requires intravenous therapy. Inhalational, gastrointestinal, or systemic anthrax requires prompt intravenous combination therapy, typically including ciprofloxacin plus one or two additional agents such as a carbapenem, rifampin, vancomycin, penicillin, chloramphenicol, or clindamycin. At least one agent with good central nervous system penetration should be included due to the risk of meningitis. In bioterrorism-related exposure, prolonged therapy for 60 days is recommended. Raxibacumab, a monoclonal antibody targeting anthrax toxin, has shown benefit in animal models of inhalational disease.
Prognosis depends on the form of disease and timeliness of treatment. Cutaneous anthrax generally responds well to therapy but often leaves a residual scar. Inhalational and gastrointestinal forms carry high mortality rates if not treated promptly. Close follow-up is required to monitor for recurrence or complications.
- Published on
Infectious Disease and Microbiology – Bacillary Angiomatosis / Peliosis Hepatica
Bacillary angiomatosis (BA) and peliosis hepatica (PH) are rare vascular proliferative infections caused by Bartonella species, most commonly affecting immunocompromised individuals, particularly those with advanced HIV infection and T-cell deficiency. Bacillary angiomatosis typically refers to the cutaneous or disseminated vascular form, whereas peliosis hepatica describes the visceral form involving blood-filled cystic lesions in the liver. If left untreated, the disease can be fatal.
This condition is globally distributed but uncommon. It is most frequently reported in individuals with HIV infection, particularly those with CD4 counts below 100 cells/mm³. Other risk factors include immunosuppression from transplantation or malignancy, poor sanitary conditions, homelessness, and close contact with cats. Bartonella henselae is most often associated with bacillary angiomatosis and cat exposure, while Bartonella quintana is linked to body louse infestation and is more commonly associated with bacteremia in homeless populations.
Preventive measures for immunocompromised individuals include careful handling of cats. Patients are advised to obtain healthy cats older than one year, practice strict hand hygiene after cleaning litter boxes, and avoid scratches or bites. Routine declawing or testing of cats is not recommended. Primary prophylaxis is generally not advised, although macrolides may offer protective effects against Bartonella infection. The need for lifelong suppressive therapy in HIV-infected patients has not been clearly established.
After an incubation period of at least one week, clinical manifestations can range from isolated bacteremia to extensive cutaneous, visceral, osseous, or central nervous system involvement. Constitutional symptoms such as fever, malaise, weight loss, and anemia are common. Peliosis hepatica often presents with persistent fever, abdominal pain, nausea, vomiting, and progressive hepatomegaly.
Cutaneous manifestations occur in the majority of patients with bacillary angiomatosis. Lesions are typically bright red, elevated papules that may vary from a few millimeters to several centimeters in size and may number from one to hundreds. Smaller lesions may have a thin overlying epidermis, while larger lesions may ulcerate or bleed easily and are often surrounded by a collarette. Subcutaneous nodules may develop without visible skin changes. Cellulitic plaque-like lesions may overlie deeper bone involvement. Extracutaneous manifestations include bone lesions, visceral involvement of the liver and spleen, lymphadenopathy, and, rarely, brain abscesses. Bone disease may present with pain alone or in association with overlying skin lesions. Peliosis hepatica is characterized by massive hepatomegaly and sometimes splenomegaly.
Diagnosis relies on tissue biopsy. Histologic examination using hematoxylin and eosin staining may show granular purple material representing organisms, while Warthin–Starry or Brown–Hopps staining can better visualize the bacteria. The organisms appear singly or in clusters. Culture is difficult and requires prolonged incubation (at least 21 days) using lysis-centrifugation techniques. Polymerase chain reaction (PCR) testing can aid in species identification. Serologic testing has limited sensitivity in immunocompromised patients. Laboratory findings may include mild elevation of transaminases, marked elevation of alkaline phosphatase, and mild-to-moderate pancytopenia in visceral disease.
Imaging findings depend on organ involvement. Bone radiographs may reveal well-circumscribed lytic lesions or cortical destruction with aggressive periosteal reaction. CT scans may demonstrate hepatosplenomegaly and abdominal lymphadenopathy, with heterogeneous liver parenchyma. Liver biopsy in peliosis hepatica shows dilated, blood-filled cystic spaces within the hepatic parenchyma, often with associated necrosis in advanced cases.
The differential diagnosis includes Kaposi’s sarcoma, pyogenic granulomas, angiomas, and other vascular tumors. Kaposi’s sarcoma may coexist with bacillary angiomatosis and should be considered, particularly if lesions fail to improve with antibiotic therapy.
Treatment begins with evaluation of the extent of organ involvement. First-line therapy consists of erythromycin 500 mg orally every six hours or doxycycline 100 mg orally twice daily. Treatment duration is generally three months for bacillary angiomatosis and four months for peliosis hepatica, with longer courses required in immunocompromised patients. A Jarisch–Herxheimer reaction may occur after initiation of therapy; pretreatment with antipyretics for the first 72 hours may help.
For patients intolerant to first-line therapy, azithromycin or clarithromycin may be used. In severe, life-threatening, or central nervous system disease—particularly in immunocompromised individuals—combination therapy with rifampin added to erythromycin or doxycycline is recommended. TMP-SMX and ciprofloxacin have shown inconsistent results. Most patients can be managed as outpatients, though hospitalization and intravenous therapy are necessary for extensive or fulminant disease.
Clinical improvement is often observed within 4–7 days of therapy, with near-complete resolution of lesions by 3–4 weeks. Relapses occur in approximately 15% of cases and may require prolonged suppressive therapy. Monitoring includes clinical assessment, serial liver function tests in visceral disease, and imaging studies for bone involvement.
Complications of visceral disease include anemia, pancytopenia due to hypersplenism, and splenic rupture with hemoperitoneum. Early recognition and prolonged antimicrobial therapy are essential for favorable outcomes.
Bacillary angiomatosis (BA) and peliosis hepatica (PH) are rare vascular proliferative infections caused by Bartonella species, most commonly affecting immunocompromised individuals, particularly those with advanced HIV infection and T-cell deficiency. Bacillary angiomatosis typically refers to the cutaneous or disseminated vascular form, whereas peliosis hepatica describes the visceral form involving blood-filled cystic lesions in the liver. If left untreated, the disease can be fatal.
This condition is globally distributed but uncommon. It is most frequently reported in individuals with HIV infection, particularly those with CD4 counts below 100 cells/mm³. Other risk factors include immunosuppression from transplantation or malignancy, poor sanitary conditions, homelessness, and close contact with cats. Bartonella henselae is most often associated with bacillary angiomatosis and cat exposure, while Bartonella quintana is linked to body louse infestation and is more commonly associated with bacteremia in homeless populations.
Preventive measures for immunocompromised individuals include careful handling of cats. Patients are advised to obtain healthy cats older than one year, practice strict hand hygiene after cleaning litter boxes, and avoid scratches or bites. Routine declawing or testing of cats is not recommended. Primary prophylaxis is generally not advised, although macrolides may offer protective effects against Bartonella infection. The need for lifelong suppressive therapy in HIV-infected patients has not been clearly established.
After an incubation period of at least one week, clinical manifestations can range from isolated bacteremia to extensive cutaneous, visceral, osseous, or central nervous system involvement. Constitutional symptoms such as fever, malaise, weight loss, and anemia are common. Peliosis hepatica often presents with persistent fever, abdominal pain, nausea, vomiting, and progressive hepatomegaly.
Cutaneous manifestations occur in the majority of patients with bacillary angiomatosis. Lesions are typically bright red, elevated papules that may vary from a few millimeters to several centimeters in size and may number from one to hundreds. Smaller lesions may have a thin overlying epidermis, while larger lesions may ulcerate or bleed easily and are often surrounded by a collarette. Subcutaneous nodules may develop without visible skin changes. Cellulitic plaque-like lesions may overlie deeper bone involvement. Extracutaneous manifestations include bone lesions, visceral involvement of the liver and spleen, lymphadenopathy, and, rarely, brain abscesses. Bone disease may present with pain alone or in association with overlying skin lesions. Peliosis hepatica is characterized by massive hepatomegaly and sometimes splenomegaly.
Diagnosis relies on tissue biopsy. Histologic examination using hematoxylin and eosin staining may show granular purple material representing organisms, while Warthin–Starry or Brown–Hopps staining can better visualize the bacteria. The organisms appear singly or in clusters. Culture is difficult and requires prolonged incubation (at least 21 days) using lysis-centrifugation techniques. Polymerase chain reaction (PCR) testing can aid in species identification. Serologic testing has limited sensitivity in immunocompromised patients. Laboratory findings may include mild elevation of transaminases, marked elevation of alkaline phosphatase, and mild-to-moderate pancytopenia in visceral disease.
Imaging findings depend on organ involvement. Bone radiographs may reveal well-circumscribed lytic lesions or cortical destruction with aggressive periosteal reaction. CT scans may demonstrate hepatosplenomegaly and abdominal lymphadenopathy, with heterogeneous liver parenchyma. Liver biopsy in peliosis hepatica shows dilated, blood-filled cystic spaces within the hepatic parenchyma, often with associated necrosis in advanced cases.
The differential diagnosis includes Kaposi’s sarcoma, pyogenic granulomas, angiomas, and other vascular tumors. Kaposi’s sarcoma may coexist with bacillary angiomatosis and should be considered, particularly if lesions fail to improve with antibiotic therapy.
Treatment begins with evaluation of the extent of organ involvement. First-line therapy consists of erythromycin 500 mg orally every six hours or doxycycline 100 mg orally twice daily. Treatment duration is generally three months for bacillary angiomatosis and four months for peliosis hepatica, with longer courses required in immunocompromised patients. A Jarisch–Herxheimer reaction may occur after initiation of therapy; pretreatment with antipyretics for the first 72 hours may help.
For patients intolerant to first-line therapy, azithromycin or clarithromycin may be used. In severe, life-threatening, or central nervous system disease—particularly in immunocompromised individuals—combination therapy with rifampin added to erythromycin or doxycycline is recommended. TMP-SMX and ciprofloxacin have shown inconsistent results. Most patients can be managed as outpatients, though hospitalization and intravenous therapy are necessary for extensive or fulminant disease.
Clinical improvement is often observed within 4–7 days of therapy, with near-complete resolution of lesions by 3–4 weeks. Relapses occur in approximately 15% of cases and may require prolonged suppressive therapy. Monitoring includes clinical assessment, serial liver function tests in visceral disease, and imaging studies for bone involvement.
Complications of visceral disease include anemia, pancytopenia due to hypersplenism, and splenic rupture with hemoperitoneum. Early recognition and prolonged antimicrobial therapy are essential for favorable outcomes.
- Published on
Infectious Disease and Microbiology – Babesiosis
Babesiosis is a protozoal infection caused by Babesia species, intraerythrocytic parasites with a predilection for human red blood cells. It is an important cause of hemolytic disease in endemic regions. The most common species in the United States is Babesia microti, transmitted primarily through the bite of Ixodes (deer) ticks. Less common modes of transmission include blood transfusion and, rarely, congenital (maternal–fetal) transmission. Most cases in the United States occur in the Northeastern and Midwestern regions, while other species such as Babesia divergens (Europe) and Babesia duncani (Western US) are also recognized.
Babesiosis is considered an emerging infectious disease, with increasing reported cases over recent decades. Expansion of deer populations, increased tick density, and greater human exposure to endemic areas contribute to rising incidence. Many infections, especially in younger and immunocompetent individuals, are asymptomatic, leading to underestimation of true prevalence. Serologic surveys in highly endemic areas show that 0.5–15% of blood donors have evidence of prior exposure.
Risk factors include residence in or travel to endemic areas, asplenia, and immunosuppression (e.g., HIV infection or chemotherapy). Preventive strategies focus on avoiding tick exposure, especially during peak transmission months (May through October). Use of insect repellents containing DEET, treatment of clothing with permethrin, daily tick checks after outdoor activity, prompt tick removal (within 24 hours), and examination of pets are recommended. Asplenic and immunocompromised individuals should exercise particular caution in endemic regions.
The life cycle of Babesia involves transmission between Ixodes ticks and vertebrate hosts, primarily white-footed mice. Humans are incidental, “dead-end” hosts and do not contribute to further transmission. After a tick bite, sporozoites enter the bloodstream and invade erythrocytes, where they develop into trophozoites. These replicate asexually to form 2–4 merozoites, which lyse red blood cells and infect additional erythrocytes, resulting in hemolysis and anemia.
Clinical presentation ranges from asymptomatic infection to severe, life-threatening disease. Common symptoms include fever, chills, weakness, headache, nausea, abdominal pain, myalgias, and dark urine. Severe cases may present with shortness of breath or chest pain. A detailed history should include recent travel to endemic areas, tick exposure, outdoor activities, pets, prior Lyme disease, or recent transfusions. Co-infection with Lyme disease or human granulocytic anaplasmosis is common because these infections share the same vector.
On physical examination, patients may have fever, pallor, jaundice, splenomegaly, and hepatomegaly. Lymphadenopathy is typically absent. In cases of Lyme co-infection, erythema migrans rash may be present.
Laboratory findings include anemia and thrombocytopenia on complete blood count, along with laboratory evidence of hemolysis such as elevated reticulocyte count, lactate dehydrogenase (LDH), and indirect bilirubin, and low haptoglobin. Thin peripheral blood smears are the cornerstone of diagnosis and may show intraerythrocytic parasites. Multiple smears over several days may be required in low parasitemia. The characteristic “Maltese cross” tetrad formation is occasionally seen and is pathognomonic when present. Unlike malaria, Babesia organisms may be observed extracellularly in heavy infection. If smears are negative but suspicion remains high, PCR testing for Babesia DNA is recommended. Serologic testing using indirect immunofluorescent antibody assays can support the diagnosis in selected cases. Imaging is usually unnecessary but may confirm splenomegaly or hepatomegaly.
Treatment for uncomplicated B. microti infection consists of oral atovaquone plus azithromycin for 7–10 days. Severe cases, including those with high parasitemia or significant symptoms, are treated with quinine plus clindamycin, administered orally or intravenously. Immunocompromised patients or those with high parasite burdens may require prolonged therapy for at least six weeks, including two weeks after clearance of parasites from blood smears. Asymptomatic immunocompetent individuals with low-level parasitemia for less than three months typically do not require treatment. In severe disease with parasitemia greater than 10% or with complications such as shock or acute respiratory distress syndrome, red blood cell exchange transfusion may be indicated.
Hospitalized patients require daily monitoring of complete blood count and peripheral blood smears to assess hemolysis and parasite burden. Patients should be educated about preventive measures to reduce the risk of reinfection.
Complications of babesiosis include disseminated intravascular coagulation, severe hemolytic anemia, congestive heart failure, acute respiratory distress syndrome, renal dysfunction, and hypotension. Severe disease is more likely in asplenic and immunocompromised individuals.
Babesiosis is a protozoal infection caused by Babesia species, intraerythrocytic parasites with a predilection for human red blood cells. It is an important cause of hemolytic disease in endemic regions. The most common species in the United States is Babesia microti, transmitted primarily through the bite of Ixodes (deer) ticks. Less common modes of transmission include blood transfusion and, rarely, congenital (maternal–fetal) transmission. Most cases in the United States occur in the Northeastern and Midwestern regions, while other species such as Babesia divergens (Europe) and Babesia duncani (Western US) are also recognized.
Babesiosis is considered an emerging infectious disease, with increasing reported cases over recent decades. Expansion of deer populations, increased tick density, and greater human exposure to endemic areas contribute to rising incidence. Many infections, especially in younger and immunocompetent individuals, are asymptomatic, leading to underestimation of true prevalence. Serologic surveys in highly endemic areas show that 0.5–15% of blood donors have evidence of prior exposure.
Risk factors include residence in or travel to endemic areas, asplenia, and immunosuppression (e.g., HIV infection or chemotherapy). Preventive strategies focus on avoiding tick exposure, especially during peak transmission months (May through October). Use of insect repellents containing DEET, treatment of clothing with permethrin, daily tick checks after outdoor activity, prompt tick removal (within 24 hours), and examination of pets are recommended. Asplenic and immunocompromised individuals should exercise particular caution in endemic regions.
The life cycle of Babesia involves transmission between Ixodes ticks and vertebrate hosts, primarily white-footed mice. Humans are incidental, “dead-end” hosts and do not contribute to further transmission. After a tick bite, sporozoites enter the bloodstream and invade erythrocytes, where they develop into trophozoites. These replicate asexually to form 2–4 merozoites, which lyse red blood cells and infect additional erythrocytes, resulting in hemolysis and anemia.
Clinical presentation ranges from asymptomatic infection to severe, life-threatening disease. Common symptoms include fever, chills, weakness, headache, nausea, abdominal pain, myalgias, and dark urine. Severe cases may present with shortness of breath or chest pain. A detailed history should include recent travel to endemic areas, tick exposure, outdoor activities, pets, prior Lyme disease, or recent transfusions. Co-infection with Lyme disease or human granulocytic anaplasmosis is common because these infections share the same vector.
On physical examination, patients may have fever, pallor, jaundice, splenomegaly, and hepatomegaly. Lymphadenopathy is typically absent. In cases of Lyme co-infection, erythema migrans rash may be present.
Laboratory findings include anemia and thrombocytopenia on complete blood count, along with laboratory evidence of hemolysis such as elevated reticulocyte count, lactate dehydrogenase (LDH), and indirect bilirubin, and low haptoglobin. Thin peripheral blood smears are the cornerstone of diagnosis and may show intraerythrocytic parasites. Multiple smears over several days may be required in low parasitemia. The characteristic “Maltese cross” tetrad formation is occasionally seen and is pathognomonic when present. Unlike malaria, Babesia organisms may be observed extracellularly in heavy infection. If smears are negative but suspicion remains high, PCR testing for Babesia DNA is recommended. Serologic testing using indirect immunofluorescent antibody assays can support the diagnosis in selected cases. Imaging is usually unnecessary but may confirm splenomegaly or hepatomegaly.
Treatment for uncomplicated B. microti infection consists of oral atovaquone plus azithromycin for 7–10 days. Severe cases, including those with high parasitemia or significant symptoms, are treated with quinine plus clindamycin, administered orally or intravenously. Immunocompromised patients or those with high parasite burdens may require prolonged therapy for at least six weeks, including two weeks after clearance of parasites from blood smears. Asymptomatic immunocompetent individuals with low-level parasitemia for less than three months typically do not require treatment. In severe disease with parasitemia greater than 10% or with complications such as shock or acute respiratory distress syndrome, red blood cell exchange transfusion may be indicated.
Hospitalized patients require daily monitoring of complete blood count and peripheral blood smears to assess hemolysis and parasite burden. Patients should be educated about preventive measures to reduce the risk of reinfection.
Complications of babesiosis include disseminated intravascular coagulation, severe hemolytic anemia, congestive heart failure, acute respiratory distress syndrome, renal dysfunction, and hypotension. Severe disease is more likely in asplenic and immunocompromised individuals.
- Published on
Infectious Disease and Microbiology – Atypical Mycobacteria (Nontuberculous Mycobacteria)
Atypical mycobacteria refer to infections caused by nontuberculous mycobacteria (NTM), a diverse group of environmental mycobacterial species distinct from Mycobacterium tuberculosis. In children, atypical mycobacteria should be considered in cases of unilateral cervical lymphadenitis, particularly in those aged 1–5 years. The swelling typically involves the anterior cervical chain, enlarges gradually, and may form fistulas through the skin. Enlarged lymph nodes are often painless, and systemic symptoms are uncommon. Most pediatric cases are caused by Mycobacterium avium complex (MAC), while M. scrofulaceum and M. tuberculosis are less frequent causes. Approximately 300 cases of MAC lymphadenitis occur annually in the United States. Overall prevalence ranges from 1 to 7.2 cases per 100,000 persons in the US, varying by region, and about half of NTM isolates represent true pathogens.
Risk factors for NTM infection include advanced age, immunosuppression, HIV infection with low CD4 counts, interferon-gamma deficiencies, and underlying structural lung disease such as bronchiectasis or chronic obstructive pulmonary disease. Genetic defects such as IFN-γ receptor 1 (IFNγR1) or interleukin-12 receptor β1 (IL-12βR1) deficiency predispose individuals to disseminated disease. In patients with AIDS and CD4 counts below 100 cells/mm³, primary prophylaxis with weekly azithromycin 1200 mg is recommended; alternatives include clarithromycin or rifabutin.
NTM are widely found in soil and water, including hot tubs and tap water. Human-to-human transmission has not been documented. Infection occurs primarily through ingestion or inhalation rather than reactivation of latent disease. Granuloma formation results from interactions between macrophages, lymphocytes, and natural killer cells. Disseminated infection arises from uncontrolled localized disease, especially in immunocompromised hosts. These organisms are aerobic, non–spore-forming bacilli with mycolic acid–containing cell walls. They are categorized by growth rate into rapid-growing mycobacteria (e.g., M. fortuitum, M. chelonae/abscessus, M. smegmatis), intermediate growers (e.g., M. marinum, M. gordonae), and slow-growing organisms (e.g., MAC, M. kansasii, M. xenopi, M. scrofulaceum, M. haemophilum, M. ulcerans).
Clinical syndromes include pulmonary disease, lymphadenitis, skin and soft tissue infection, osteoarticular disease, catheter-related infection, and disseminated disease. Pulmonary infection typically presents with chronic productive cough and may progress to weight loss, fatigue, dyspnea, hemoptysis, and chest pain. Soft tissue infections often follow trauma, surgery, or aquatic exposure and appear as papular or ulcerative lesions that may spread along lymphatics. Lymphadenitis usually manifests as painless or mildly tender enlargement of submandibular or jugular lymph nodes. Disseminated disease, most commonly seen in advanced HIV infection, presents with fever, fatigue, anorexia, and laboratory abnormalities such as pancytopenia or elevated alkaline phosphatase.
Diagnosis requires correlation of clinical, radiographic, and microbiologic findings because NTM may represent colonization rather than true infection. In pulmonary disease, chest imaging may show upper-lobe cavitary lesions, nodular or reticulonodular infiltrates, or adenopathy. Cavitary disease is common in MAC pulmonary infections and typically involves thin-walled cavities measuring 2–4 cm. At least three sputum samples (or bronchoalveolar lavage specimens) should be obtained for acid-fast bacillus smear and culture. Mycobacterial blood cultures are positive in approximately 90% of disseminated MAC cases. Tissue biopsy demonstrating granulomas with giant cells and acid-fast bacilli supports localized infection, whereas well-formed granulomas may be absent in disseminated disease. Definitive identification and susceptibility testing should be performed at specialized laboratories.
Treatment depends on the species and site of infection and often requires prolonged multidrug therapy. Pulmonary MAC is treated with rifampin, ethambutol, and a macrolide (azithromycin or clarithromycin), sometimes with an aminoglycoside for severe disease. Therapy continues for at least 12 months after cultures become negative. Pulmonary infection with M. kansasii is treated with isoniazid, rifampin, and ethambutol. Rapid-growing mycobacteria causing soft tissue infections are treated with two active agents based on susceptibility testing, such as trimethoprim–sulfamethoxazole, doxycycline, levofloxacin, or clarithromycin. Severe M. abscessus infections may require amikacin combined with clarithromycin and cefoxitin or imipenem. Disseminated MAC in HIV patients is treated with a macrolide plus ethambutol, with consideration of adding rifampin.
Surgical management may be necessary in selected cases. Resection of affected lymph nodes in MAC lymphadenitis achieves cure in approximately 90% of pediatric cases without antimicrobials. Lung resection may be considered in localized refractory pulmonary disease. Incision and drainage are often required for soft tissue infections.
Long-term follow-up is essential because therapy may last months to years and drug toxicities are common. Patients require regular laboratory monitoring, evaluation for drug–drug interactions, and sometimes therapeutic drug monitoring. Prognosis depends on the infecting species, the site of disease, and the host’s immune status. Complications include ulceration and fistula formation in lymphadenitis and, rarely, gastrointestinal complications such as intussusception or obstruction in disseminated MAC.
Atypical mycobacteria refer to infections caused by nontuberculous mycobacteria (NTM), a diverse group of environmental mycobacterial species distinct from Mycobacterium tuberculosis. In children, atypical mycobacteria should be considered in cases of unilateral cervical lymphadenitis, particularly in those aged 1–5 years. The swelling typically involves the anterior cervical chain, enlarges gradually, and may form fistulas through the skin. Enlarged lymph nodes are often painless, and systemic symptoms are uncommon. Most pediatric cases are caused by Mycobacterium avium complex (MAC), while M. scrofulaceum and M. tuberculosis are less frequent causes. Approximately 300 cases of MAC lymphadenitis occur annually in the United States. Overall prevalence ranges from 1 to 7.2 cases per 100,000 persons in the US, varying by region, and about half of NTM isolates represent true pathogens.
Risk factors for NTM infection include advanced age, immunosuppression, HIV infection with low CD4 counts, interferon-gamma deficiencies, and underlying structural lung disease such as bronchiectasis or chronic obstructive pulmonary disease. Genetic defects such as IFN-γ receptor 1 (IFNγR1) or interleukin-12 receptor β1 (IL-12βR1) deficiency predispose individuals to disseminated disease. In patients with AIDS and CD4 counts below 100 cells/mm³, primary prophylaxis with weekly azithromycin 1200 mg is recommended; alternatives include clarithromycin or rifabutin.
NTM are widely found in soil and water, including hot tubs and tap water. Human-to-human transmission has not been documented. Infection occurs primarily through ingestion or inhalation rather than reactivation of latent disease. Granuloma formation results from interactions between macrophages, lymphocytes, and natural killer cells. Disseminated infection arises from uncontrolled localized disease, especially in immunocompromised hosts. These organisms are aerobic, non–spore-forming bacilli with mycolic acid–containing cell walls. They are categorized by growth rate into rapid-growing mycobacteria (e.g., M. fortuitum, M. chelonae/abscessus, M. smegmatis), intermediate growers (e.g., M. marinum, M. gordonae), and slow-growing organisms (e.g., MAC, M. kansasii, M. xenopi, M. scrofulaceum, M. haemophilum, M. ulcerans).
Clinical syndromes include pulmonary disease, lymphadenitis, skin and soft tissue infection, osteoarticular disease, catheter-related infection, and disseminated disease. Pulmonary infection typically presents with chronic productive cough and may progress to weight loss, fatigue, dyspnea, hemoptysis, and chest pain. Soft tissue infections often follow trauma, surgery, or aquatic exposure and appear as papular or ulcerative lesions that may spread along lymphatics. Lymphadenitis usually manifests as painless or mildly tender enlargement of submandibular or jugular lymph nodes. Disseminated disease, most commonly seen in advanced HIV infection, presents with fever, fatigue, anorexia, and laboratory abnormalities such as pancytopenia or elevated alkaline phosphatase.
Diagnosis requires correlation of clinical, radiographic, and microbiologic findings because NTM may represent colonization rather than true infection. In pulmonary disease, chest imaging may show upper-lobe cavitary lesions, nodular or reticulonodular infiltrates, or adenopathy. Cavitary disease is common in MAC pulmonary infections and typically involves thin-walled cavities measuring 2–4 cm. At least three sputum samples (or bronchoalveolar lavage specimens) should be obtained for acid-fast bacillus smear and culture. Mycobacterial blood cultures are positive in approximately 90% of disseminated MAC cases. Tissue biopsy demonstrating granulomas with giant cells and acid-fast bacilli supports localized infection, whereas well-formed granulomas may be absent in disseminated disease. Definitive identification and susceptibility testing should be performed at specialized laboratories.
Treatment depends on the species and site of infection and often requires prolonged multidrug therapy. Pulmonary MAC is treated with rifampin, ethambutol, and a macrolide (azithromycin or clarithromycin), sometimes with an aminoglycoside for severe disease. Therapy continues for at least 12 months after cultures become negative. Pulmonary infection with M. kansasii is treated with isoniazid, rifampin, and ethambutol. Rapid-growing mycobacteria causing soft tissue infections are treated with two active agents based on susceptibility testing, such as trimethoprim–sulfamethoxazole, doxycycline, levofloxacin, or clarithromycin. Severe M. abscessus infections may require amikacin combined with clarithromycin and cefoxitin or imipenem. Disseminated MAC in HIV patients is treated with a macrolide plus ethambutol, with consideration of adding rifampin.
Surgical management may be necessary in selected cases. Resection of affected lymph nodes in MAC lymphadenitis achieves cure in approximately 90% of pediatric cases without antimicrobials. Lung resection may be considered in localized refractory pulmonary disease. Incision and drainage are often required for soft tissue infections.
Long-term follow-up is essential because therapy may last months to years and drug toxicities are common. Patients require regular laboratory monitoring, evaluation for drug–drug interactions, and sometimes therapeutic drug monitoring. Prognosis depends on the infecting species, the site of disease, and the host’s immune status. Complications include ulceration and fistula formation in lymphadenitis and, rarely, gastrointestinal complications such as intussusception or obstruction in disseminated MAC.
- Published on
Infectious Disease and Microbiology – Aspergillosis
Aspergillosis describes a spectrum of illnesses caused by species of Aspergillus, ranging from simple colonization or allergic reactions to localized or disseminated invasive disease. Although virtually any organ may be involved, the lungs are most commonly affected, followed by the paranasal sinuses and, less frequently, the central nervous system.
The number of Aspergillus species implicated in human disease continues to expand. Aspergillus fumigatus remains the most common cause of invasive infection, but A. flavus, A. terreus, A. niger, and A. versicolor are increasingly recognized. Invasive aspergillosis is second only to candidiasis among invasive fungal infections in immunocompromised patients. Major risk factors include granulocytopenia (the most significant), hematopoietic stem cell transplantation, solid-organ transplantation, acute leukemia, prolonged corticosteroid or cytotoxic therapy, chronic obstructive pulmonary disease treated with steroids, prolonged antibiotic use, liver failure, diabetes mellitus, chronic granulomatous disease, and advanced AIDS (CD4 count ≤50 cells/mm³). Genetic polymorphisms in Toll-like receptors 4 and 9 may influence susceptibility to invasive aspergillosis and allergic bronchopulmonary aspergillosis (ABPA), respectively.
Preventive strategies focus on environmental control, particularly during hospital construction activities, to reduce exposure to airborne conidia. High-efficiency particulate air (HEPA) filtration systems are recommended for high-risk patients. In selected individuals with prior invasive disease who may become neutropenic, antifungal prophylaxis with agents such as voriconazole or amphotericin B may be considered.
Pathophysiologically, inhaled conidia are small enough to reach the alveoli. In immunocompetent hosts, alveolar macrophages clear the spores. In immunocompromised individuals, impaired macrophage function allows germination into hyphae, triggering inflammatory cytokine release, vascular invasion, tissue necrosis, and possible hematogenous dissemination. In ABPA, colonization in atopic individuals activates TH2 CD4+ T cells, driving IgE production and eosinophilia, exacerbating asthma and potentially leading to bronchiectasis. Chronic pulmonary aspergillosis, including aspergilloma formation, often develops in patients with prior lung disease such as tuberculosis, lung cancer resection, ABPA, or bullous disease.
Clinical manifestations vary by syndrome. ABPA occurs in patients with asthma or cystic fibrosis and presents with worsening respiratory symptoms, malaise, and occasionally hemoptysis. Chronic pulmonary aspergillosis typically presents with weight loss, chronic cough, hemoptysis, dyspnea, and constitutional symptoms. Invasive aspergillosis commonly presents with fever, pleuritic chest pain, cough, dyspnea, and hemoptysis, especially in neutropenic or otherwise immunocompromised hosts.
Diagnosis depends on clinical suspicion and supportive laboratory and imaging findings. In ABPA, chest imaging may show upper-lobe infiltrates, bronchial wall thickening, bronchiectasis, or ground-glass opacities. Peripheral eosinophilia, elevated total serum IgE, positive immediate skin test to Aspergillus, and elevated serum IgG to A. fumigatus support the diagnosis. Chronic pulmonary aspergillosis is characterized radiographically by one or more lung cavities, sometimes containing a mobile aspergilloma with an air-crescent sign. Invasive aspergillosis requires demonstration of fungal invasion on tissue biopsy for definitive diagnosis. Serum galactomannan and β-glucan assays are useful adjunctive tests, particularly in high-risk patients.
Treatment depends on disease type. ABPA is managed with systemic glucocorticoids combined with itraconazole, with steroids tapered over several months when possible. Chronic pulmonary aspergillosis often requires long-term antifungal therapy, commonly with voriconazole, and in selected cases surgical resection of aspergilloma. Embolization may be used to control hemoptysis. Invasive aspergillosis is treated with voriconazole as first-line therapy. Alternatives include amphotericin B, itraconazole, or echinocandins, although combination therapy remains of uncertain benefit. Surgical debridement is recommended when feasible.
Patients with invasive disease require prompt initiation of antifungal therapy and stabilization of hemodynamic parameters. Hospital admission is warranted for unstable patients, those with significant hemoptysis, or immunocompromised individuals with fever. Long-term monitoring is essential to detect relapse, progression, or drug toxicity. Therapeutic drug monitoring of voriconazole trough levels is recommended during prolonged therapy.
Prognosis depends largely on the degree of immunosuppression and fungal burden. Complications include massive hemoptysis in chronic disease, pulmonary fibrosis and bronchiectasis in ABPA, pneumothorax, empyema, and disseminated infection in invasive disease. Central nervous system involvement may result in vascular occlusion and severe neurologic sequelae. Early recognition and aggressive management are critical to improving outcomes.
Aspergillosis describes a spectrum of illnesses caused by species of Aspergillus, ranging from simple colonization or allergic reactions to localized or disseminated invasive disease. Although virtually any organ may be involved, the lungs are most commonly affected, followed by the paranasal sinuses and, less frequently, the central nervous system.
The number of Aspergillus species implicated in human disease continues to expand. Aspergillus fumigatus remains the most common cause of invasive infection, but A. flavus, A. terreus, A. niger, and A. versicolor are increasingly recognized. Invasive aspergillosis is second only to candidiasis among invasive fungal infections in immunocompromised patients. Major risk factors include granulocytopenia (the most significant), hematopoietic stem cell transplantation, solid-organ transplantation, acute leukemia, prolonged corticosteroid or cytotoxic therapy, chronic obstructive pulmonary disease treated with steroids, prolonged antibiotic use, liver failure, diabetes mellitus, chronic granulomatous disease, and advanced AIDS (CD4 count ≤50 cells/mm³). Genetic polymorphisms in Toll-like receptors 4 and 9 may influence susceptibility to invasive aspergillosis and allergic bronchopulmonary aspergillosis (ABPA), respectively.
Preventive strategies focus on environmental control, particularly during hospital construction activities, to reduce exposure to airborne conidia. High-efficiency particulate air (HEPA) filtration systems are recommended for high-risk patients. In selected individuals with prior invasive disease who may become neutropenic, antifungal prophylaxis with agents such as voriconazole or amphotericin B may be considered.
Pathophysiologically, inhaled conidia are small enough to reach the alveoli. In immunocompetent hosts, alveolar macrophages clear the spores. In immunocompromised individuals, impaired macrophage function allows germination into hyphae, triggering inflammatory cytokine release, vascular invasion, tissue necrosis, and possible hematogenous dissemination. In ABPA, colonization in atopic individuals activates TH2 CD4+ T cells, driving IgE production and eosinophilia, exacerbating asthma and potentially leading to bronchiectasis. Chronic pulmonary aspergillosis, including aspergilloma formation, often develops in patients with prior lung disease such as tuberculosis, lung cancer resection, ABPA, or bullous disease.
Clinical manifestations vary by syndrome. ABPA occurs in patients with asthma or cystic fibrosis and presents with worsening respiratory symptoms, malaise, and occasionally hemoptysis. Chronic pulmonary aspergillosis typically presents with weight loss, chronic cough, hemoptysis, dyspnea, and constitutional symptoms. Invasive aspergillosis commonly presents with fever, pleuritic chest pain, cough, dyspnea, and hemoptysis, especially in neutropenic or otherwise immunocompromised hosts.
Diagnosis depends on clinical suspicion and supportive laboratory and imaging findings. In ABPA, chest imaging may show upper-lobe infiltrates, bronchial wall thickening, bronchiectasis, or ground-glass opacities. Peripheral eosinophilia, elevated total serum IgE, positive immediate skin test to Aspergillus, and elevated serum IgG to A. fumigatus support the diagnosis. Chronic pulmonary aspergillosis is characterized radiographically by one or more lung cavities, sometimes containing a mobile aspergilloma with an air-crescent sign. Invasive aspergillosis requires demonstration of fungal invasion on tissue biopsy for definitive diagnosis. Serum galactomannan and β-glucan assays are useful adjunctive tests, particularly in high-risk patients.
Treatment depends on disease type. ABPA is managed with systemic glucocorticoids combined with itraconazole, with steroids tapered over several months when possible. Chronic pulmonary aspergillosis often requires long-term antifungal therapy, commonly with voriconazole, and in selected cases surgical resection of aspergilloma. Embolization may be used to control hemoptysis. Invasive aspergillosis is treated with voriconazole as first-line therapy. Alternatives include amphotericin B, itraconazole, or echinocandins, although combination therapy remains of uncertain benefit. Surgical debridement is recommended when feasible.
Patients with invasive disease require prompt initiation of antifungal therapy and stabilization of hemodynamic parameters. Hospital admission is warranted for unstable patients, those with significant hemoptysis, or immunocompromised individuals with fever. Long-term monitoring is essential to detect relapse, progression, or drug toxicity. Therapeutic drug monitoring of voriconazole trough levels is recommended during prolonged therapy.
Prognosis depends largely on the degree of immunosuppression and fungal burden. Complications include massive hemoptysis in chronic disease, pulmonary fibrosis and bronchiectasis in ABPA, pneumothorax, empyema, and disseminated infection in invasive disease. Central nervous system involvement may result in vascular occlusion and severe neurologic sequelae. Early recognition and aggressive management are critical to improving outcomes.
- Published on
Infectious Disease and Microbiology – Antibiotic and Clostridium difficile-Related Diarrhea
Antibiotic-associated diarrhea and colitis describe a spectrum of clinical syndromes that occur during or within 4–6 weeks after antibiotic therapy, resulting from disruption of normal intestinal flora. The diagnosis requires exclusion of other identifiable causes of diarrhea. Based on the degree of colonic involvement, disease ranges from normal colonic mucosa to mild erythema and edema, granular or hemorrhagic mucosa, and pseudomembrane formation. Clostridium difficile is the most common identifiable cause of antibiotic-associated colitis.
In the United States, C. difficile is responsible for approximately 3 million cases of diarrhea and colitis annually, with most cases occurring in hospitals or long-term care facilities, although community-acquired cases are increasingly recognized. Transmission occurs via spores spread from patient to patient, often through contaminated environmental surfaces and healthcare workers’ hands or equipment. While toxigenic C. difficile can be isolated from about 3% of healthy adults, colonization frequently develops during hospitalization, and roughly one-third of colonized individuals become symptomatic.
Major risk factors include antibiotic exposure, particularly clindamycin, ampicillin, amoxicillin, and cephalosporins, though virtually all broad-spectrum antibiotics can predispose to infection. Additional risk factors include hospitalization, advanced age, and severe underlying illness. Prevention strategies focus on strict enteric isolation precautions, use of gloves, private rooms when possible, and avoidance of unnecessary antibiotic use.
The pathogenesis begins with disruption of normal colonic flora, allowing C. difficile to proliferate. Most toxigenic strains produce two exotoxins, toxin A and toxin B. Toxin A is primarily responsible for enterotoxic effects, while toxin B is a potent cytotoxin. These toxins cause mucosal injury, inflammation, and in severe cases, pseudomembranous colitis.
Clinical presentation varies widely. Mild to moderate disease typically manifests with watery diarrhea and lower abdominal cramping without systemic symptoms. Moderate to severe colitis may present with profuse diarrhea, abdominal pain and distention, fever, nausea, anorexia, and malaise. Occult bleeding may occur. A subset of patients presents predominantly with right-sided colonic disease, marked leukocytosis, and abdominal pain but minimal diarrhea. Fulminant colitis may lead to ileus, toxic megacolon, or perforation. In contrast, non–C. difficile antibiotic-associated diarrhea is usually mild, dose-related, lacks systemic symptoms, and resolves rapidly after discontinuation of the offending antibiotic.
Physical examination may reveal abdominal tenderness ranging from mild to severe, and in advanced cases signs of peritonitis or systemic toxicity. Laboratory testing commonly includes enzyme immunoassay (EIA) for toxins A and B, complete blood count, and inflammatory markers. Leukocytosis with left shift is common, with white blood cell counts typically between 12,000 and 20,000/mm³, though leukemoid reactions can occur. Stool culture for C. difficile is rarely used because it does not differentiate toxigenic from non-toxigenic strains. Tissue culture cytotoxicity assay for toxin B is highly sensitive and specific but less commonly performed due to technical requirements and delayed results. Imaging with abdominal CT may demonstrate colonic wall thickening or edema. Endoscopy is reserved for selected cases, particularly when rapid diagnosis is needed or stool samples are unavailable.
Management begins with discontinuation of the inciting antibiotic whenever possible and supportive care with fluid and electrolyte replacement. Antiperistaltic agents should be avoided. Mild cases may resolve without specific therapy, but moderate or severe infections require targeted antimicrobial treatment. Oral metronidazole (500 mg three times daily) or oral vancomycin (125 mg four times daily) for 10–14 days are standard therapies. Metronidazole is often preferred initially due to lower cost and reduced risk of promoting vancomycin-resistant organisms, while vancomycin is preferred for severe disease, pregnancy, or in children under 10 years of age. Critically ill patients unable to take oral therapy may require rectal vancomycin administration or surgical intervention, such as subtotal colectomy.
Relapse occurs in 10–20% of patients, and recurrent episodes may require repeat therapy or tapered vancomycin regimens over several weeks. Fecal microbiota transplantation has been used successfully in severe or recurrent cases.
Complications include fulminant colitis, ileus, perforation, toxic megacolon, hyperpyrexia, reactive arthritis, chronic diarrhea, and hypoalbuminemia with anasarca. Monitoring should focus on clinical symptoms, as routine post-treatment testing is not recommended unless symptoms recur. Early recognition and prompt management are critical to reducing morbidity and mortality associated with severe disease.
Antibiotic-associated diarrhea and colitis describe a spectrum of clinical syndromes that occur during or within 4–6 weeks after antibiotic therapy, resulting from disruption of normal intestinal flora. The diagnosis requires exclusion of other identifiable causes of diarrhea. Based on the degree of colonic involvement, disease ranges from normal colonic mucosa to mild erythema and edema, granular or hemorrhagic mucosa, and pseudomembrane formation. Clostridium difficile is the most common identifiable cause of antibiotic-associated colitis.
In the United States, C. difficile is responsible for approximately 3 million cases of diarrhea and colitis annually, with most cases occurring in hospitals or long-term care facilities, although community-acquired cases are increasingly recognized. Transmission occurs via spores spread from patient to patient, often through contaminated environmental surfaces and healthcare workers’ hands or equipment. While toxigenic C. difficile can be isolated from about 3% of healthy adults, colonization frequently develops during hospitalization, and roughly one-third of colonized individuals become symptomatic.
Major risk factors include antibiotic exposure, particularly clindamycin, ampicillin, amoxicillin, and cephalosporins, though virtually all broad-spectrum antibiotics can predispose to infection. Additional risk factors include hospitalization, advanced age, and severe underlying illness. Prevention strategies focus on strict enteric isolation precautions, use of gloves, private rooms when possible, and avoidance of unnecessary antibiotic use.
The pathogenesis begins with disruption of normal colonic flora, allowing C. difficile to proliferate. Most toxigenic strains produce two exotoxins, toxin A and toxin B. Toxin A is primarily responsible for enterotoxic effects, while toxin B is a potent cytotoxin. These toxins cause mucosal injury, inflammation, and in severe cases, pseudomembranous colitis.
Clinical presentation varies widely. Mild to moderate disease typically manifests with watery diarrhea and lower abdominal cramping without systemic symptoms. Moderate to severe colitis may present with profuse diarrhea, abdominal pain and distention, fever, nausea, anorexia, and malaise. Occult bleeding may occur. A subset of patients presents predominantly with right-sided colonic disease, marked leukocytosis, and abdominal pain but minimal diarrhea. Fulminant colitis may lead to ileus, toxic megacolon, or perforation. In contrast, non–C. difficile antibiotic-associated diarrhea is usually mild, dose-related, lacks systemic symptoms, and resolves rapidly after discontinuation of the offending antibiotic.
Physical examination may reveal abdominal tenderness ranging from mild to severe, and in advanced cases signs of peritonitis or systemic toxicity. Laboratory testing commonly includes enzyme immunoassay (EIA) for toxins A and B, complete blood count, and inflammatory markers. Leukocytosis with left shift is common, with white blood cell counts typically between 12,000 and 20,000/mm³, though leukemoid reactions can occur. Stool culture for C. difficile is rarely used because it does not differentiate toxigenic from non-toxigenic strains. Tissue culture cytotoxicity assay for toxin B is highly sensitive and specific but less commonly performed due to technical requirements and delayed results. Imaging with abdominal CT may demonstrate colonic wall thickening or edema. Endoscopy is reserved for selected cases, particularly when rapid diagnosis is needed or stool samples are unavailable.
Management begins with discontinuation of the inciting antibiotic whenever possible and supportive care with fluid and electrolyte replacement. Antiperistaltic agents should be avoided. Mild cases may resolve without specific therapy, but moderate or severe infections require targeted antimicrobial treatment. Oral metronidazole (500 mg three times daily) or oral vancomycin (125 mg four times daily) for 10–14 days are standard therapies. Metronidazole is often preferred initially due to lower cost and reduced risk of promoting vancomycin-resistant organisms, while vancomycin is preferred for severe disease, pregnancy, or in children under 10 years of age. Critically ill patients unable to take oral therapy may require rectal vancomycin administration or surgical intervention, such as subtotal colectomy.
Relapse occurs in 10–20% of patients, and recurrent episodes may require repeat therapy or tapered vancomycin regimens over several weeks. Fecal microbiota transplantation has been used successfully in severe or recurrent cases.
Complications include fulminant colitis, ileus, perforation, toxic megacolon, hyperpyrexia, reactive arthritis, chronic diarrhea, and hypoalbuminemia with anasarca. Monitoring should focus on clinical symptoms, as routine post-treatment testing is not recommended unless symptoms recur. Early recognition and prompt management are critical to reducing morbidity and mortality associated with severe disease.
- Published on
Infectious Disease and Microbiology – Amebiasis
Amebiasis is a protozoal infection caused by Entamoeba histolytica. Infection may result in asymptomatic colonization, diarrhea, colitis, or invasive extra-intestinal disease, most commonly liver abscess. Although approximately 10% of the global population is estimated to be infected, symptomatic disease develops in fewer than 10% of infected individuals, and only a small proportion of those with intestinal infection progress to invasive disease.
Prevalence varies geographically, ranging from less than 5% in developed countries to 20–30% in tropical regions. In the United States, prevalence is estimated at under 4%. Infection occurs at all ages and affects both sexes equally. In endemic areas, risk factors include low socioeconomic status, poor sanitation, and overcrowding. In low-prevalence regions, infection is more common among immigrants and travelers from endemic areas, institutionalized individuals, and men who have sex with men. Severe disease is more likely in neonates, pregnant women, malnourished individuals, and those receiving corticosteroid therapy.
Humans are the only reservoir. Transmission occurs via the fecal–oral route, typically through ingestion of contaminated water or food. Chlorination does not reliably destroy cysts; boiling water is required for effective decontamination. Proper washing of vegetables with potable water or treatment with detergent and vinegar reduces risk. The organism exists in two forms: the trophozoite, which may contain ingested erythrocytes, and the quadrinucleate cyst, which is the infective form. After ingestion, excystation occurs in the small intestine, releasing trophozoites that colonize the colon. Most infected individuals remain asymptomatic cyst passers. In invasive disease, trophozoites penetrate the colonic mucosa, producing characteristic flask-shaped ulcers. Cysts can survive for months in moist environments.
Several Entamoeba species infect humans, but E. histolytica is the primary pathogenic species. Morphologically similar nonpathogenic species include Entamoeba dispar, Entamoeba moshkovskii, Entamoeba hartmanni, and Entamoeba coli.
Clinical manifestations depend on the extent of invasion. Symptoms of intestinal disease usually develop within four weeks of cyst ingestion. Asymptomatic infection is common. Noninvasive disease presents with mild diarrhea. Amebic colitis or dysentery causes crampy abdominal pain, bloody and mucoid diarrhea, rectal bleeding (especially in children), fever in about one-third of patients, weight loss, and anorexia. Extra-intestinal disease most frequently involves the liver, with abscess formation developing approximately three months after infection. Patients present with fever and right upper quadrant pain, and half may not recall prior colitis. Abscess rupture can cause peritonitis, empyema, or pleural involvement. Cerebral amebiasis is rare but presents with headache, nausea, vomiting, and altered mental status.
On examination, colitis may produce diffuse abdominal tenderness, distention, and signs of peritonitis in severe cases. Liver abscess is associated with right upper quadrant tenderness, hepatomegaly, and rarely jaundice.
Diagnosis relies on stool microscopy, antigen detection, serology, imaging, and sometimes biopsy. Stool ova and parasite examination may reveal trophozoites with ingested red blood cells. Multiple stool samples increase sensitivity. Fecal antigen detection by ELISA is more sensitive than microscopy but less sensitive than PCR. Serology is useful in invasive disease and liver abscess, though antibodies may persist for years and are less helpful in endemic regions. Leukocytosis without eosinophilia is common in invasive disease, and liver abscess may show elevated alkaline phosphatase and mild transaminase elevations. Imaging with ultrasound, CT, or MRI typically demonstrates a right-lobe liver abscess. Colonoscopy may reveal friable mucosa and flask-shaped ulcers. Aspiration of a liver abscess yields characteristic brown, odorless “anchovy paste” material, although organisms are often not recovered from the fluid itself.
Differential diagnosis includes ulcerative colitis, Crohn’s disease, colorectal carcinoma, diverticulitis, abdominal abscess, pyogenic liver abscess, hepatoma, echinococcal cyst, and irritable bowel syndrome.
Treatment depends on clinical presentation. Asymptomatic luminal infection should be treated to prevent invasive disease, typically with paromomycin for seven days, or alternatives such as diloxanide furoate or iodoquinol. Amebic colitis requires metronidazole or tinidazole followed by a luminal agent such as paromomycin or iodoquinol to eradicate cysts. Amebic liver abscess is treated with metronidazole followed by a luminal agent. Large abscesses greater than 3 cm may require needle aspiration or drainage, whereas smaller abscesses usually respond to medical therapy alone.
Follow-up imaging is recommended after treatment of liver abscess to confirm resolution, which may take several months. Amebiasis carries significant morbidity and mortality in developing countries. Complications include fulminant colitis with toxic megacolon, perforation, peritonitis, formation of amebomas that mimic colon cancer, bowel obstruction, and rupture of liver abscess into pleural or pericardial spaces.
Amebiasis is a protozoal infection caused by Entamoeba histolytica. Infection may result in asymptomatic colonization, diarrhea, colitis, or invasive extra-intestinal disease, most commonly liver abscess. Although approximately 10% of the global population is estimated to be infected, symptomatic disease develops in fewer than 10% of infected individuals, and only a small proportion of those with intestinal infection progress to invasive disease.
Prevalence varies geographically, ranging from less than 5% in developed countries to 20–30% in tropical regions. In the United States, prevalence is estimated at under 4%. Infection occurs at all ages and affects both sexes equally. In endemic areas, risk factors include low socioeconomic status, poor sanitation, and overcrowding. In low-prevalence regions, infection is more common among immigrants and travelers from endemic areas, institutionalized individuals, and men who have sex with men. Severe disease is more likely in neonates, pregnant women, malnourished individuals, and those receiving corticosteroid therapy.
Humans are the only reservoir. Transmission occurs via the fecal–oral route, typically through ingestion of contaminated water or food. Chlorination does not reliably destroy cysts; boiling water is required for effective decontamination. Proper washing of vegetables with potable water or treatment with detergent and vinegar reduces risk. The organism exists in two forms: the trophozoite, which may contain ingested erythrocytes, and the quadrinucleate cyst, which is the infective form. After ingestion, excystation occurs in the small intestine, releasing trophozoites that colonize the colon. Most infected individuals remain asymptomatic cyst passers. In invasive disease, trophozoites penetrate the colonic mucosa, producing characteristic flask-shaped ulcers. Cysts can survive for months in moist environments.
Several Entamoeba species infect humans, but E. histolytica is the primary pathogenic species. Morphologically similar nonpathogenic species include Entamoeba dispar, Entamoeba moshkovskii, Entamoeba hartmanni, and Entamoeba coli.
Clinical manifestations depend on the extent of invasion. Symptoms of intestinal disease usually develop within four weeks of cyst ingestion. Asymptomatic infection is common. Noninvasive disease presents with mild diarrhea. Amebic colitis or dysentery causes crampy abdominal pain, bloody and mucoid diarrhea, rectal bleeding (especially in children), fever in about one-third of patients, weight loss, and anorexia. Extra-intestinal disease most frequently involves the liver, with abscess formation developing approximately three months after infection. Patients present with fever and right upper quadrant pain, and half may not recall prior colitis. Abscess rupture can cause peritonitis, empyema, or pleural involvement. Cerebral amebiasis is rare but presents with headache, nausea, vomiting, and altered mental status.
On examination, colitis may produce diffuse abdominal tenderness, distention, and signs of peritonitis in severe cases. Liver abscess is associated with right upper quadrant tenderness, hepatomegaly, and rarely jaundice.
Diagnosis relies on stool microscopy, antigen detection, serology, imaging, and sometimes biopsy. Stool ova and parasite examination may reveal trophozoites with ingested red blood cells. Multiple stool samples increase sensitivity. Fecal antigen detection by ELISA is more sensitive than microscopy but less sensitive than PCR. Serology is useful in invasive disease and liver abscess, though antibodies may persist for years and are less helpful in endemic regions. Leukocytosis without eosinophilia is common in invasive disease, and liver abscess may show elevated alkaline phosphatase and mild transaminase elevations. Imaging with ultrasound, CT, or MRI typically demonstrates a right-lobe liver abscess. Colonoscopy may reveal friable mucosa and flask-shaped ulcers. Aspiration of a liver abscess yields characteristic brown, odorless “anchovy paste” material, although organisms are often not recovered from the fluid itself.
Differential diagnosis includes ulcerative colitis, Crohn’s disease, colorectal carcinoma, diverticulitis, abdominal abscess, pyogenic liver abscess, hepatoma, echinococcal cyst, and irritable bowel syndrome.
Treatment depends on clinical presentation. Asymptomatic luminal infection should be treated to prevent invasive disease, typically with paromomycin for seven days, or alternatives such as diloxanide furoate or iodoquinol. Amebic colitis requires metronidazole or tinidazole followed by a luminal agent such as paromomycin or iodoquinol to eradicate cysts. Amebic liver abscess is treated with metronidazole followed by a luminal agent. Large abscesses greater than 3 cm may require needle aspiration or drainage, whereas smaller abscesses usually respond to medical therapy alone.
Follow-up imaging is recommended after treatment of liver abscess to confirm resolution, which may take several months. Amebiasis carries significant morbidity and mortality in developing countries. Complications include fulminant colitis with toxic megacolon, perforation, peritonitis, formation of amebomas that mimic colon cancer, bowel obstruction, and rupture of liver abscess into pleural or pericardial spaces.
- Published on
Infectious Disease and Microbiology – Appendicitis
Appendicitis is inflammation of the appendix and is one of the most common surgical emergencies. When the blood supply to the appendix becomes compromised, the condition is termed gangrenous appendicitis. If the inflamed appendix ruptures, it is referred to as perforating appendicitis. When luminal obstruction is the precipitating factor, the condition is described as obstructive appendicitis.
Appendectomy remains the most frequent indication for abdominal surgery. In the United States, at least 250,000 cases of appendicitis occur annually, accounting for more than one million inpatient hospital days. Interestingly, the appendix is found to be normal in up to one-third of patients undergoing emergency appendectomy. Missed appendicitis is among the most common causes of successful malpractice claims against emergency department physicians. Males are affected slightly more often than females, with a male-to-female ratio of approximately 3:2. The lifetime risk is about 8.5% in men and 6.7% in women. Although appendicitis can occur at any age, peak incidence is in the second and third decades of life. Perforation is more common in infants and elderly patients.
The pathogenesis typically begins with luminal obstruction, most commonly caused by a fecalith. Other causes include foreign bodies, lymphoid hyperplasia (often associated with viral infections such as measles), parasitic worms, or tumors such as carcinoid or carcinoma. Obstruction leads to accumulation of mucus, bacterial overgrowth, and invasion of the appendiceal wall. Rising intraluminal pressure causes venous congestion, arterial compromise, ischemia, gangrene, and ultimately perforation. Ruptured appendiceal abscesses may form fistulas. Occasionally, appendicitis may be the first manifestation of Crohn’s disease, and in rare cases, recurrent acute appendicitis can occur with complete resolution between episodes.
Microbiologically, overgrowth of gastrointestinal flora occurs within the obstructed appendix. Common organisms include Escherichia coli, Bacteroides fragilis, Peptostreptococcus, Enterobacteriaceae, and viridans streptococci. Chronic infections due to tuberculosis, amebiasis, or actinomycosis are rare but documented causes.
Clinically, appendicitis classically begins with poorly localized, colicky periumbilical or epigastric pain due to visceral inflammation. As inflammation extends to the parietal peritoneum, pain becomes steady, more severe, and localized to the right lower quadrant at McBurney’s point. Movement and coughing aggravate the pain. Anorexia is common, and its absence should prompt reconsideration of the diagnosis. Nausea and vomiting occur in about half of patients, but vomiting rarely precedes pain. Urinary frequency or dysuria may occur if the inflamed appendix lies near the bladder.
Physical examination findings evolve with disease progression. Right lower quadrant tenderness eventually develops. Guarding, rebound tenderness, and percussion tenderness reflect peritoneal irritation. Rovsing’s sign refers to right lower quadrant pain elicited by palpation of the left lower quadrant. The psoas sign (pain with passive right hip extension) and obturator sign (pain with internal rotation of the flexed right hip) suggest retrocecal or pelvic appendiceal position. Fever is usually mild; temperatures above 38.3°C suggest perforation. A palpable right lower quadrant mass may indicate abscess formation or, less commonly, malignancy.
Laboratory evaluation commonly reveals leukocytosis between 10,000 and 18,000 cells/mm³ with a left shift, though normal white blood cell counts do not exclude appendicitis. Pregnancy testing is essential in women of childbearing age. Imaging plays a critical role in diagnosis. Computed tomography (CT) has an accuracy greater than 90% and improves resource utilization. Ultrasound is particularly useful in children and women of reproductive age to exclude gynecologic pathology. However, normal imaging should not override a convincing clinical picture.
The primary treatment is prompt surgical removal of the appendix. Preoperative antibiotics targeting gram-negative aerobes and anaerobes are standard. Regimens may include beta-lactam/beta-lactamase inhibitor combinations, ceftriaxone plus metronidazole, fluoroquinolone plus metronidazole, or carbapenems. Both laparoscopic and open appendectomy are acceptable approaches. Laparoscopic surgery is associated with less postoperative pain and fewer wound infections, though slightly higher rates of intra-abdominal abscess and increased cost.
In cases where a palpable mass develops several days after symptom onset, suggesting phlegmon formation, surgery may be delayed. These patients are managed with broad-spectrum antibiotics, intravenous fluids, and rest, with interval appendectomy performed approximately three months later unless clinical deterioration necessitates earlier intervention.
Prognosis is generally excellent, with mortality rates less than 1 per 100,000 in developed countries. However, perforated appendicitis carries a mortality rate of approximately 3%, rising to 15% in elderly patients. Delayed diagnosis increases the risk of perforation, which significantly raises postoperative complication rates, including intra-abdominal abscess, peritonitis, and wound infection. Rare complications include portal vein thrombophlebitis and pyogenic liver abscess. Early recognition and timely surgical management remain essential to prevent morbidity and mortality.
Appendicitis is inflammation of the appendix and is one of the most common surgical emergencies. When the blood supply to the appendix becomes compromised, the condition is termed gangrenous appendicitis. If the inflamed appendix ruptures, it is referred to as perforating appendicitis. When luminal obstruction is the precipitating factor, the condition is described as obstructive appendicitis.
Appendectomy remains the most frequent indication for abdominal surgery. In the United States, at least 250,000 cases of appendicitis occur annually, accounting for more than one million inpatient hospital days. Interestingly, the appendix is found to be normal in up to one-third of patients undergoing emergency appendectomy. Missed appendicitis is among the most common causes of successful malpractice claims against emergency department physicians. Males are affected slightly more often than females, with a male-to-female ratio of approximately 3:2. The lifetime risk is about 8.5% in men and 6.7% in women. Although appendicitis can occur at any age, peak incidence is in the second and third decades of life. Perforation is more common in infants and elderly patients.
The pathogenesis typically begins with luminal obstruction, most commonly caused by a fecalith. Other causes include foreign bodies, lymphoid hyperplasia (often associated with viral infections such as measles), parasitic worms, or tumors such as carcinoid or carcinoma. Obstruction leads to accumulation of mucus, bacterial overgrowth, and invasion of the appendiceal wall. Rising intraluminal pressure causes venous congestion, arterial compromise, ischemia, gangrene, and ultimately perforation. Ruptured appendiceal abscesses may form fistulas. Occasionally, appendicitis may be the first manifestation of Crohn’s disease, and in rare cases, recurrent acute appendicitis can occur with complete resolution between episodes.
Microbiologically, overgrowth of gastrointestinal flora occurs within the obstructed appendix. Common organisms include Escherichia coli, Bacteroides fragilis, Peptostreptococcus, Enterobacteriaceae, and viridans streptococci. Chronic infections due to tuberculosis, amebiasis, or actinomycosis are rare but documented causes.
Clinically, appendicitis classically begins with poorly localized, colicky periumbilical or epigastric pain due to visceral inflammation. As inflammation extends to the parietal peritoneum, pain becomes steady, more severe, and localized to the right lower quadrant at McBurney’s point. Movement and coughing aggravate the pain. Anorexia is common, and its absence should prompt reconsideration of the diagnosis. Nausea and vomiting occur in about half of patients, but vomiting rarely precedes pain. Urinary frequency or dysuria may occur if the inflamed appendix lies near the bladder.
Physical examination findings evolve with disease progression. Right lower quadrant tenderness eventually develops. Guarding, rebound tenderness, and percussion tenderness reflect peritoneal irritation. Rovsing’s sign refers to right lower quadrant pain elicited by palpation of the left lower quadrant. The psoas sign (pain with passive right hip extension) and obturator sign (pain with internal rotation of the flexed right hip) suggest retrocecal or pelvic appendiceal position. Fever is usually mild; temperatures above 38.3°C suggest perforation. A palpable right lower quadrant mass may indicate abscess formation or, less commonly, malignancy.
Laboratory evaluation commonly reveals leukocytosis between 10,000 and 18,000 cells/mm³ with a left shift, though normal white blood cell counts do not exclude appendicitis. Pregnancy testing is essential in women of childbearing age. Imaging plays a critical role in diagnosis. Computed tomography (CT) has an accuracy greater than 90% and improves resource utilization. Ultrasound is particularly useful in children and women of reproductive age to exclude gynecologic pathology. However, normal imaging should not override a convincing clinical picture.
The primary treatment is prompt surgical removal of the appendix. Preoperative antibiotics targeting gram-negative aerobes and anaerobes are standard. Regimens may include beta-lactam/beta-lactamase inhibitor combinations, ceftriaxone plus metronidazole, fluoroquinolone plus metronidazole, or carbapenems. Both laparoscopic and open appendectomy are acceptable approaches. Laparoscopic surgery is associated with less postoperative pain and fewer wound infections, though slightly higher rates of intra-abdominal abscess and increased cost.
In cases where a palpable mass develops several days after symptom onset, suggesting phlegmon formation, surgery may be delayed. These patients are managed with broad-spectrum antibiotics, intravenous fluids, and rest, with interval appendectomy performed approximately three months later unless clinical deterioration necessitates earlier intervention.
Prognosis is generally excellent, with mortality rates less than 1 per 100,000 in developed countries. However, perforated appendicitis carries a mortality rate of approximately 3%, rising to 15% in elderly patients. Delayed diagnosis increases the risk of perforation, which significantly raises postoperative complication rates, including intra-abdominal abscess, peritonitis, and wound infection. Rare complications include portal vein thrombophlebitis and pyogenic liver abscess. Early recognition and timely surgical management remain essential to prevent morbidity and mortality.
- Published on
Infectious Disease and Microbiology – Anorectal Infections
Anorectal infections involve the anus and rectum, the distal portion of the large intestine. These infections range from sexually transmitted diseases and perianal abscesses to life-threatening necrotizing infections such as Fournier’s gangrene, which affects the external genitalia and perineum. In organ transplant recipients, the prevalence of external anogenital lesions ranges from 1.5% to 2.3%, with women more commonly affected. Most lesions are due to anogenital warts, followed by bowenoid papulosis, giant condyloma, and in situ carcinoma.
Risk factors for severe anorectal infections such as Fournier’s gangrene include prior urinary tract infections, urologic instrumentation, and chronic colorectal disease. Many affected patients have comorbid conditions such as diabetes mellitus, alcoholism, or intravenous drug use, which impair host immune defenses. In immunocompromised individuals, perianal abscesses and fistulas must be promptly identified and treated with adequate drainage or fistulectomy to prevent progression to necrotizing infection or metastatic abscess formation.
Pathophysiology varies by cause. Primary anal or rectal infections commonly occur after receptive anorectal intercourse, particularly among men who have sex with men and in women. Rectal infection with Chlamydia trachomatis (including lymphogranuloma venereum strains) may result from direct inoculation or contiguous spread from genital secretions. Herpes simplex virus (HSV-1 and HSV-2) can cause symptomatic or asymptomatic proctitis and perianal disease; viral shedding may occur even in individuals without a history of rectal intercourse. Perianal warts caused by human papillomavirus (HPV) are common in both men who have sex with men and heterosexual men. Perirectal abscesses may arise from extension of infection related to diverticulitis, Crohn’s disease, ulcerative colitis, or previous surgery. Fournier’s gangrene is typically polymicrobial, involving mixed aerobic and anaerobic organisms.
Common infectious causes include bacterial and parasitic pathogens as well as sexually transmitted infections. Among men who have sex with men, frequent causes include anorectal gonorrhea, HSV, syphilis, Chlamydia trachomatis, and enteric pathogens such as Giardia lamblia, Entamoeba histolytica, and Campylobacter species. In patients with HIV infection, perirectal ulcers due to HSV reactivation are common, along with condyloma acuminatum, Kaposi’s sarcoma, and intraepithelial neoplasia. Diabetes mellitus (type I and II) is commonly associated with severe soft tissue infections in this region.
Clinical manifestations depend on the etiology. HSV proctitis typically presents with anorectal pain, discharge, tenesmus, and constipation. Anogenital warts appear as cauliflower-like condyloma acuminata on moist surfaces, keratotic papules on dry surfaces, or flat subclinical lesions on mucosal or cutaneous areas. Fournier’s gangrene presents with severe pain that may be disproportionate to physical findings, massive swelling of the scrotum and penis, erythema, bullae, and progression to gangrene extending into the perineum or abdominal wall. Systemic toxicity may develop rapidly.
Diagnosis includes laboratory and imaging studies. Anorectal swabs with PCR testing are useful for detecting C. trachomatis. In HSV infection, sigmoidoscopy may reveal ulcerative lesions in the distal rectum, and biopsy may show mucosal ulceration with multinucleated cells containing viral inclusions. Laboratory tests such as complete blood count, inflammatory markers, metabolic panels, creatine phosphokinase, glucose levels, and arterial blood gases are important in severely ill patients. CT or MRI imaging helps assess abscess formation or soft tissue involvement. Differential diagnosis includes condylomata lata of secondary syphilis, molluscum contagiosum, neoplasms, and donovanosis, particularly in endemic regions.
Management depends on the specific infection. Cryotherapy may be effective for genital warts that do not respond to topical therapy, though perianal warts may be more resistant. Perianal abscesses require prompt drainage and antibiotics. Fournier’s gangrene requires immediate and aggressive surgical exploration with debridement of necrotic tissue, reduction of compartment pressure, and collection of cultures. Broad-spectrum intravenous antibiotics covering aerobic and anaerobic organisms are essential; regimens may include clindamycin combined with ampicillin or ampicillin–sulbactam plus gentamicin. Hyperbaric oxygen therapy may be beneficial in selected cases, particularly with clostridial involvement. Patients often require intensive care management.
Follow-up is important, particularly in patients with anal warts and HIV infection, as both are independent risk factors for anal cytologic abnormalities and precancerous lesions. High-risk groups, including men with HPV infection, intravenous drug users, and organ transplant recipients, may benefit from anal cytology screening. Complications include secondary infection of warts, bleeding, mechanical obstruction, perianal sepsis in immunocompromised individuals, and septicemia in Fournier’s gangrene, which carries a mortality rate ranging from 22% to 66%.
Anorectal infections involve the anus and rectum, the distal portion of the large intestine. These infections range from sexually transmitted diseases and perianal abscesses to life-threatening necrotizing infections such as Fournier’s gangrene, which affects the external genitalia and perineum. In organ transplant recipients, the prevalence of external anogenital lesions ranges from 1.5% to 2.3%, with women more commonly affected. Most lesions are due to anogenital warts, followed by bowenoid papulosis, giant condyloma, and in situ carcinoma.
Risk factors for severe anorectal infections such as Fournier’s gangrene include prior urinary tract infections, urologic instrumentation, and chronic colorectal disease. Many affected patients have comorbid conditions such as diabetes mellitus, alcoholism, or intravenous drug use, which impair host immune defenses. In immunocompromised individuals, perianal abscesses and fistulas must be promptly identified and treated with adequate drainage or fistulectomy to prevent progression to necrotizing infection or metastatic abscess formation.
Pathophysiology varies by cause. Primary anal or rectal infections commonly occur after receptive anorectal intercourse, particularly among men who have sex with men and in women. Rectal infection with Chlamydia trachomatis (including lymphogranuloma venereum strains) may result from direct inoculation or contiguous spread from genital secretions. Herpes simplex virus (HSV-1 and HSV-2) can cause symptomatic or asymptomatic proctitis and perianal disease; viral shedding may occur even in individuals without a history of rectal intercourse. Perianal warts caused by human papillomavirus (HPV) are common in both men who have sex with men and heterosexual men. Perirectal abscesses may arise from extension of infection related to diverticulitis, Crohn’s disease, ulcerative colitis, or previous surgery. Fournier’s gangrene is typically polymicrobial, involving mixed aerobic and anaerobic organisms.
Common infectious causes include bacterial and parasitic pathogens as well as sexually transmitted infections. Among men who have sex with men, frequent causes include anorectal gonorrhea, HSV, syphilis, Chlamydia trachomatis, and enteric pathogens such as Giardia lamblia, Entamoeba histolytica, and Campylobacter species. In patients with HIV infection, perirectal ulcers due to HSV reactivation are common, along with condyloma acuminatum, Kaposi’s sarcoma, and intraepithelial neoplasia. Diabetes mellitus (type I and II) is commonly associated with severe soft tissue infections in this region.
Clinical manifestations depend on the etiology. HSV proctitis typically presents with anorectal pain, discharge, tenesmus, and constipation. Anogenital warts appear as cauliflower-like condyloma acuminata on moist surfaces, keratotic papules on dry surfaces, or flat subclinical lesions on mucosal or cutaneous areas. Fournier’s gangrene presents with severe pain that may be disproportionate to physical findings, massive swelling of the scrotum and penis, erythema, bullae, and progression to gangrene extending into the perineum or abdominal wall. Systemic toxicity may develop rapidly.
Diagnosis includes laboratory and imaging studies. Anorectal swabs with PCR testing are useful for detecting C. trachomatis. In HSV infection, sigmoidoscopy may reveal ulcerative lesions in the distal rectum, and biopsy may show mucosal ulceration with multinucleated cells containing viral inclusions. Laboratory tests such as complete blood count, inflammatory markers, metabolic panels, creatine phosphokinase, glucose levels, and arterial blood gases are important in severely ill patients. CT or MRI imaging helps assess abscess formation or soft tissue involvement. Differential diagnosis includes condylomata lata of secondary syphilis, molluscum contagiosum, neoplasms, and donovanosis, particularly in endemic regions.
Management depends on the specific infection. Cryotherapy may be effective for genital warts that do not respond to topical therapy, though perianal warts may be more resistant. Perianal abscesses require prompt drainage and antibiotics. Fournier’s gangrene requires immediate and aggressive surgical exploration with debridement of necrotic tissue, reduction of compartment pressure, and collection of cultures. Broad-spectrum intravenous antibiotics covering aerobic and anaerobic organisms are essential; regimens may include clindamycin combined with ampicillin or ampicillin–sulbactam plus gentamicin. Hyperbaric oxygen therapy may be beneficial in selected cases, particularly with clostridial involvement. Patients often require intensive care management.
Follow-up is important, particularly in patients with anal warts and HIV infection, as both are independent risk factors for anal cytologic abnormalities and precancerous lesions. High-risk groups, including men with HPV infection, intravenous drug users, and organ transplant recipients, may benefit from anal cytology screening. Complications include secondary infection of warts, bleeding, mechanical obstruction, perianal sepsis in immunocompromised individuals, and septicemia in Fournier’s gangrene, which carries a mortality rate ranging from 22% to 66%.
- Published on
Infectious Disease and Microbiology – Anaerobic Infections
Anaerobic infections are caused by bacteria that require reduced oxygen tension for growth. Most anaerobes involved in human disease are aerotolerant, meaning they can survive but not replicate in oxygenated environments for up to 72 hours. These organisms normally colonize mucosal surfaces, including the oral cavity, gastrointestinal tract, and female genital tract, and commonly cause infections that originate from these sites. Anaerobes account for up to 10% of clinically significant bloodstream infections, although precise incidence data for other infection sites are limited.
Risk factors include disruption of mucosal barriers due to malignancy, chemotherapy, radiation, neutropenia, graft-versus-host disease, surgery, trauma, inflammatory bowel disease, diverticulitis, or appendicitis. Poor dental hygiene predisposes to oral and pulmonary infections. Conditions such as altered mental status, impaired swallowing, or depressed gag reflex increase the risk of aspiration and subsequent anaerobic lung infections. Preventive strategies include perioperative antimicrobial prophylaxis, bowel preparation when indicated, maintenance of good dental hygiene, and aspiration precautions.
Pathogenesis involves translocation of resident anaerobic flora into normally sterile tissues following mucosal disruption. Aspiration introduces oral anaerobes into the lungs. In polymicrobial infections, aerobic bacteria may reduce the oxidation–reduction potential, facilitating anaerobic growth. Virulence factors contribute to abscess formation and immune evasion; for example, Bacteroides fragilis produces capsular polysaccharide, Prevotella species produce IgA proteases, Porphyromonas gingivalis produces proteases, and Fusobacterium necrophorum produces leukotoxin and endotoxin.
The most common anaerobic Gram-negative bacillus is Bacteroides fragilis. Other important Gram-negative genera include Fusobacterium, Prevotella, and Porphyromonas. Among Gram-positive organisms, Peptostreptococcus species are common cocci, and Clostridium species are major Gram-positive rods associated with disease.
Anaerobes are implicated in a wide range of infections. Oral and dental infections include pulpitis, dental abscesses, perimandibular space infections, gingivitis, periodontitis, and periodontal abscesses. Severe head and neck infections include Vincent’s stomatitis (trench mouth), Ludwig’s angina involving sublingual and submandibular spaces, and Lemierre syndrome, characterized by F. necrophorum infection with internal jugular vein thrombophlebitis and septic pulmonary emboli. Pleuropulmonary manifestations include aspiration pneumonia, necrotizing pneumonia, lung abscess, and empyema. Intraabdominal infections include peritonitis, abscesses, and neutropenic colitis (typhlitis). Female genital tract infections include pelvic inflammatory disease, tubo-ovarian abscess, septic abortion, endometritis, and bacterial vaginosis. Central nervous system involvement may present as brain abscess, epidural abscess, subdural empyema, or rarely anaerobic meningitis. Skin and soft tissue infections include necrotizing fasciitis, gas gangrene, bite wounds, diabetic foot infections, and infected surgical wounds. Anaerobic bacteremia often arises secondary to intraabdominal, genital tract, respiratory, or soft tissue infections, with B. fragilis being the most common isolate.
Clinical features depend on the site of infection. Foul odor, abscess formation, tissue necrosis, and infection adjacent to mucosal surfaces suggest anaerobic involvement. Gas in tissues with crepitus indicates infection by gas-forming organisms. Vincent’s stomatitis presents with tender bleeding gums, halitosis, fever, and lymphadenopathy. Ludwig’s angina causes submandibular pain, trismus, tongue displacement, and potential airway compromise. Lemierre syndrome follows oropharyngeal infection with high fever, neck tenderness, and pulmonary metastases. Anaerobic lung abscess presents with chronic malaise, foul-smelling sputum, fever, and anemia. Typhlitis presents with neutropenia, right lower quadrant pain, fever, and diarrhea. Lack of response to antibiotics without anaerobic coverage should raise suspicion.
Diagnosis is challenging because anaerobes are difficult to culture. Proper specimen collection is critical: aspirated fluids or tissue samples are preferred over swabs, air must be excluded from syringes, and specimens require anaerobic transport media with rapid processing. Gram staining is essential; the presence of organisms on Gram stain without growth in culture suggests anaerobes. Imaging may reveal air–fluid levels, cavitation, or gas in tissues. CT or MRI helps define extent of disease. Image-guided aspiration or biopsy may be required. Anaerobic lung abscess must be differentiated from mycobacterial infection.
Management requires both surgical and antimicrobial therapy. Drainage, debridement, or resection is often essential. Empiric antibiotics should provide coverage for both aerobic and anaerobic organisms due to frequent polymicrobial infection. Infections below the diaphragm require specific coverage for B. fragilis, which is resistant to penicillin. Effective agents include carbapenems, beta-lactam/beta-lactamase inhibitor combinations, and metronidazole, although metronidazole lacks activity against Actinomyces, Propionibacterium, Peptostreptococcus, and microaerophilic streptococci. Resistance among B. fragilis to clindamycin, cephamycins, and fluoroquinolones has increased. Susceptibility testing is recommended in cases requiring prolonged therapy, such as brain abscess or osteomyelitis.
Close follow-up is necessary to ensure adequate abscess drainage and clinical response. Repeat imaging and sampling may be needed if there is no improvement. Monitoring for antimicrobial toxicity is important. Untreated infections may spread contiguously, leading to serious complications.
Anaerobic infections are caused by bacteria that require reduced oxygen tension for growth. Most anaerobes involved in human disease are aerotolerant, meaning they can survive but not replicate in oxygenated environments for up to 72 hours. These organisms normally colonize mucosal surfaces, including the oral cavity, gastrointestinal tract, and female genital tract, and commonly cause infections that originate from these sites. Anaerobes account for up to 10% of clinically significant bloodstream infections, although precise incidence data for other infection sites are limited.
Risk factors include disruption of mucosal barriers due to malignancy, chemotherapy, radiation, neutropenia, graft-versus-host disease, surgery, trauma, inflammatory bowel disease, diverticulitis, or appendicitis. Poor dental hygiene predisposes to oral and pulmonary infections. Conditions such as altered mental status, impaired swallowing, or depressed gag reflex increase the risk of aspiration and subsequent anaerobic lung infections. Preventive strategies include perioperative antimicrobial prophylaxis, bowel preparation when indicated, maintenance of good dental hygiene, and aspiration precautions.
Pathogenesis involves translocation of resident anaerobic flora into normally sterile tissues following mucosal disruption. Aspiration introduces oral anaerobes into the lungs. In polymicrobial infections, aerobic bacteria may reduce the oxidation–reduction potential, facilitating anaerobic growth. Virulence factors contribute to abscess formation and immune evasion; for example, Bacteroides fragilis produces capsular polysaccharide, Prevotella species produce IgA proteases, Porphyromonas gingivalis produces proteases, and Fusobacterium necrophorum produces leukotoxin and endotoxin.
The most common anaerobic Gram-negative bacillus is Bacteroides fragilis. Other important Gram-negative genera include Fusobacterium, Prevotella, and Porphyromonas. Among Gram-positive organisms, Peptostreptococcus species are common cocci, and Clostridium species are major Gram-positive rods associated with disease.
Anaerobes are implicated in a wide range of infections. Oral and dental infections include pulpitis, dental abscesses, perimandibular space infections, gingivitis, periodontitis, and periodontal abscesses. Severe head and neck infections include Vincent’s stomatitis (trench mouth), Ludwig’s angina involving sublingual and submandibular spaces, and Lemierre syndrome, characterized by F. necrophorum infection with internal jugular vein thrombophlebitis and septic pulmonary emboli. Pleuropulmonary manifestations include aspiration pneumonia, necrotizing pneumonia, lung abscess, and empyema. Intraabdominal infections include peritonitis, abscesses, and neutropenic colitis (typhlitis). Female genital tract infections include pelvic inflammatory disease, tubo-ovarian abscess, septic abortion, endometritis, and bacterial vaginosis. Central nervous system involvement may present as brain abscess, epidural abscess, subdural empyema, or rarely anaerobic meningitis. Skin and soft tissue infections include necrotizing fasciitis, gas gangrene, bite wounds, diabetic foot infections, and infected surgical wounds. Anaerobic bacteremia often arises secondary to intraabdominal, genital tract, respiratory, or soft tissue infections, with B. fragilis being the most common isolate.
Clinical features depend on the site of infection. Foul odor, abscess formation, tissue necrosis, and infection adjacent to mucosal surfaces suggest anaerobic involvement. Gas in tissues with crepitus indicates infection by gas-forming organisms. Vincent’s stomatitis presents with tender bleeding gums, halitosis, fever, and lymphadenopathy. Ludwig’s angina causes submandibular pain, trismus, tongue displacement, and potential airway compromise. Lemierre syndrome follows oropharyngeal infection with high fever, neck tenderness, and pulmonary metastases. Anaerobic lung abscess presents with chronic malaise, foul-smelling sputum, fever, and anemia. Typhlitis presents with neutropenia, right lower quadrant pain, fever, and diarrhea. Lack of response to antibiotics without anaerobic coverage should raise suspicion.
Diagnosis is challenging because anaerobes are difficult to culture. Proper specimen collection is critical: aspirated fluids or tissue samples are preferred over swabs, air must be excluded from syringes, and specimens require anaerobic transport media with rapid processing. Gram staining is essential; the presence of organisms on Gram stain without growth in culture suggests anaerobes. Imaging may reveal air–fluid levels, cavitation, or gas in tissues. CT or MRI helps define extent of disease. Image-guided aspiration or biopsy may be required. Anaerobic lung abscess must be differentiated from mycobacterial infection.
Management requires both surgical and antimicrobial therapy. Drainage, debridement, or resection is often essential. Empiric antibiotics should provide coverage for both aerobic and anaerobic organisms due to frequent polymicrobial infection. Infections below the diaphragm require specific coverage for B. fragilis, which is resistant to penicillin. Effective agents include carbapenems, beta-lactam/beta-lactamase inhibitor combinations, and metronidazole, although metronidazole lacks activity against Actinomyces, Propionibacterium, Peptostreptococcus, and microaerophilic streptococci. Resistance among B. fragilis to clindamycin, cephamycins, and fluoroquinolones has increased. Susceptibility testing is recommended in cases requiring prolonged therapy, such as brain abscess or osteomyelitis.
Close follow-up is necessary to ensure adequate abscess drainage and clinical response. Repeat imaging and sampling may be needed if there is no improvement. Monitoring for antimicrobial toxicity is important. Untreated infections may spread contiguously, leading to serious complications.
